Methotrexate in combination with radiotherapy in the treatment of squamous carcinomas of the head and neck.
D000284:Administration, Oral; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002610:Cheek / Q000473:pathology; D003037:Cobalt Radioisotopes; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008048:Lip Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D008441:Maxillary Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009062:Mouth Neoplasms / Q000628:therapy*; D010307:Parotid Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011867:Radioisotope Teletherapy; D014062:Tongue Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D014067:Tonsillar Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*
D003037:Cobalt Radioisotopes; D008727:Methotrexate